Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

被引：0
|
作者：
Mohammed A Aleskandarany
Andrew R Green
Ahmed A Benhasouna
Fabricio F Barros
Keith Neal
Jorge S Reis-Filho
Ian O Ellis
Emad A Rakha
机构：
[1] University of Nottingham and Nottingham University Hospitals NHS Trust,Department of Histopathology, School of Molecular Medical Sciences, Queens Medical Centre
[2] Menoufia University,Pathology Department, Faculty of Medicine
[3] Shebin El-Kom,Occupational Health, School of Molecular Medical Sciences, Queens Medical Centre
[4] University of Nottingham and Nottingham University Hospitals NHS Trust,Breakthrough Breast Cancer Research Centre
[5] Institute of Cancer Research,undefined
来源：
Breast Cancer Research | / 14卷
关键词：
Breast Cancer; Mitotic Count; Breast Cancer Specific Survival; Luminal Tumor; Invasive Breast Cancer Case;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Prognostic value of BRCA mutations in triple-negative breast cancer
    Guerrero-Setas, D.
    Freire, J.
    Garcia-Berbel, P.
    Ruiz De Azua, Y.
    De la Cruz, S.
    Armendariz, P.
    Mercado, M. D. R.
    Aguiar, B.
    Arriola, M.
    Gomez-Roman, J.
    Cordoba, A.
    VIRCHOWS ARCHIV, 2020, 477 : S143 - S144
  • [42] Prognostic Value of Multiple Triple-Negative Markers in Breast Cancer
    Lu, S.
    Walter, O.
    Vohra, P.
    Kandil, D.
    Wang, L. J.
    Mercurio, A. M.
    Khan, A.
    LABORATORY INVESTIGATION, 2010, 90 : 60A - 61A
  • [43] The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review
    Wankhade, Dhanashree
    Gharde, Pankaj
    Dutta, Sushmita
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [44] Treatment of HER2-positive and triple-negative Breast Cancer Significant Survival Benefits with Tucatinib and Sacituzumab-Govitecan
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (03) : 144 - 144
  • [45] Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
    Kang, Byeongju
    Lee, Jeeyeon
    Jung, Jin Hyang
    Kim, Wan Wook
    Keum, Heejung
    Park, Ho Yong
    MEDICINE, 2023, 102 (34) : E34772
  • [46] Genomic Insights into Triple-Negative and HER2-Positive Breast Cancers Using Isogenic Model Systems
    Mudvari, Prakriti
    Ohshiro, Kazufumi
    Nair, Vasudha
    Horvath, Anelia
    Kumar, Rakesh
    PLOS ONE, 2013, 8 (09):
  • [47] Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
    Johanna Alanko
    Minna Tanner
    Ritva Vanninen
    Anssi Auvinen
    Jorma Isola
    Breast Cancer Research and Treatment, 2021, 187 : 267 - 274
  • [48] Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
    Alanko, Johanna
    Tanner, Minna
    Vanninen, Ritva
    Auvinen, Anssi
    Isola, Jorma
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (01) : 267 - 274
  • [49] Prognostic value of HER2-positive circulating tumor cells in breast cancer patients
    Wuelfing, Pia
    Borchard, Julia
    Buerger, Horst
    Heidl, Stefan
    Zaenker, Kurt S.
    Kiesel, Ludwig
    Brandt, Burkhard
    CANCER RESEARCH, 2006, 66 (08)
  • [50] Increases in Tumor N-Glycan Polylactosamines Associated with Advanced HER2-Positive and Triple-Negative Breast Cancer Tissues
    Scott, Danielle A.
    Casadonte, Rita
    Cardinali, Barbara
    Spruill, Laura
    Mehta, Anand S.
    Carli, Franca
    Simone, Nicole
    Kriegsmann, Mark
    Del Mastro, Lucia
    Kriegsmann, Joerg
    Drake, Richard R.
    PROTEOMICS CLINICAL APPLICATIONS, 2019, 13 (01)
12345